VERA LUCIA JORNADA KREBS
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Definitions of Sepsis in Neonatology: A Fundamental Tool(2015) KREBS, Vera Lucia Jornada; YOSHIDA, Renata de Araujo Monteiro; DELGADO, Artur Figueiredo; CARVALHO, Werther Brunow de
conferenceObject ACTIVE SEARCH FOR 22q11.2 DELETION IN INFANTS WITH CONGENITAL HEART DISEASE UNDERGOING CORRECTIVE SURGERY: PRELIMINARY RESULTS(2015) GRASSI, Marcilia Sierro; KULIKOWSKI, Leslie Domenici; JACOB, Cristina Miuki Abe; DUTRA, Roberta Lelis; ZANARDO, Evelin; CECCON, Maria Esther Jurfest Rivero; KREBS, Vera Lucia Jornada; IKARI, Nana Miura; JATENE, Marcelo Biscegli; CARVALHO, Werther Brunow; CARNEIRO-SAMPAIO, Magda- Menkes disease: importance of diagnosis with molecular analysis in the neonatal period(2015) COSTA, Larissa Sampaio de Athayde; PEGLER, Stephanie Pucci; LELLIS, Rute Facchini; KREBS, Vera Lucia Jornada; ROBERTSON, Stephen; MORGAN, Tim; HONJO, Rachel Sayuri; BERTOLA, Debora Romeo; KIM, Chong AeMenkes disease is a congenital disorder caused by changes in copper metabolism derived from mutations in the ATP7A gene. It is characterized by physical and neurological alterations. In the neonatal period, these alterations can be nonspecific, which makes early diagnosis a challenge. Diagnosis can be suspected when there are low levels of ceruloplasmin and serum copper. Molecular analysis confirms the diagnosis. Treatment is parenteral administration of copper histidine. We report a familial case with molecular confirmation. The proband had clinical and biochemical suspicious. Treatment with copper histidine was indicated, but initiated at the age of 2 months and 27 days only. He did not present improvements and died at 6 months. The mother became pregnant again, a male fetus was identified and copper histidine was manufactured during pregnancy. He was born healthy, biochemical markers were reduced and treatment was indicated. Molecular analysis was performed confirming mutation in both the mother and the proband, while the other son did not have mutation, so treatment was discontinued. We support the clinical relevance of molecular confirmation for the correct diagnosis and genetic counseling, once clinical findings in the neonatal period are nonspecific and early treatment with parenteral copper histidine must be indicated.
- Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study(2015) BRIZOT, Maria L.; HERNANDEZ, Wagner; LIAO, Adolfo W.; BITTAR, Roberto E.; FRANCISCO, Rossana P. V.; KREBS, Vera L. J.; ZUGAIB, MarceloOBJECTIVE: The purpose of this study was to investigate the use of vaginal progesterone for the prevention of preterm delivery in twin pregnancies. STUDY DESIGN: We conducted a prospective, randomized, doubleblind, placebo-controlled trial that involved 390 naturally conceived twin pregnancies among mothers with no history of preterm delivery who were receiving antenatal care at a single center. Women with twin pregnancies between 18 and 21 weeks and 6 days' gestation were assigned randomly to daily vaginal progesterone (200 mg) or placebo ovules until 34 weeks and 6 days' gestation. The primary outcome was the difference in mean gestational age at delivery; the secondary outcomes were the rate of spontaneous delivery at <34 weeks' gestation and the rate of neonatal composite morbidity and mortality in the treatment and nontreatment groups. RESULTS: The baseline characteristics were similar in both groups. The final analysis included 189 women in the progesterone group and 191 in the placebo group. No difference (P = .095) in the mean gestational age at delivery was observed between progesterone (35.08 +/- 3.19 [SD]) and placebo groups (35.55 +/- 2.85). The incidence of spontaneous delivery at <34 weeks' gestation was 18.5% in the progesterone group and 14.6% in the placebo group (odds ratio, 1.32; 95% confidence interval, 0.24-2.37). No difference in the composite neonatal morbidity and mortality was observed between the progesterone (15.5%) and placebo (15.9%) groups (odds ratio, 1.01; 95% confidence interval, 0.58-1.75). CONCLUSION: In nonselected twin pregnancies, vaginal progesterone administration does not prevent preterm delivery and does not reduce neonatal morbidity and death.
- Palmar grasp behavior in full-term newborns in the first 72 hours of life(2015) DIONISIO, Jadiane; MORAES, Marcus Vinicius Marques de; TUDELLA, Eloisa; CARVALHO, Werther Brunow de; KREBS, Vera Lucia JornadaBackground: The palmar grasp behavior is one of the items of an infants routine neurological tests. Its exacerbated presence after the fifth month of age or absence in the first day after birth is an important sign of neuro-sensorimotor disorders. This study aimed to describe the palmar grasp behavior of full-term newborns in the first 72 h of life. Methods: This nonrandomized cross-sectional developmental study included 219 typical newborns aged 12-24 h, 25-48 h and 49-72 h. Three measurements were performed with newborns in the supine position, recording the palmar grasp rime and strength. Statistical analysis was applied with significant level of p < 0.05. Results: Higher palmar grasp strength was observed in newborns aged 49-72 h compared to newborns aged 12-24 h and 25-48 h (F = 7.42, p = 0.01). There was significant difference in palmar grasp strength between hands (F = 6.55, p = 0.01), only in 12-24 h, with greater strength in the left hand (t = -2.43, p = 0.01), and difference in palmar grasp between strength (F = 18.7, p = 0.01) with greater strength in females (t = -5.40, p = 0.01) only at the age 48-72 h. Conclusions: It was concluded that the palmar grasp behavior modifies in the first 72 h of life.